<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03121599</url>
  </required_header>
  <id_info>
    <org_study_id>16294/16</org_study_id>
    <nct_id>NCT03121599</nct_id>
  </id_info>
  <brief_title>18F-FLT (PET/CT) in Pediatrics With Myeloproliferative Neoplasms</brief_title>
  <official_title>A Study of 18F-FLT Positron Emission Tomography (PET)/Computed Tomography Imaging in Pediatrics With Myeloproliferative Neoplasms</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hamad Medical Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hamad Medical Corporation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>No</is_unapproved_device>
    <is_ppsd>No</is_ppsd>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Main purpose of this project to study the uptake pattern of FLT-PET and it is value in
      assessing the malignant hematopoiesis in MPN within the pediatric age group, in terms of
      diagnosis, staging and monitoring response to therapy. As well as, evaluating FLT-PET as a
      novel non-invasive technique in cases with MPN and its role in comparison to the standard
      bone marrow biopsy with regard to disease diagnosis, assessment of disease activity,
      detection of transformation, monitoring of treatment response and grading of
      fibrosis.Furthermore, we aim to study the association of FLT-PET uptake patterns with
      different genetic makeup (JAK2, CALR positive, MPL, or Triple negative disease) or allele
      burden in cases of Pre-PMF with the ability of FLT-PET to differentiate between Pre-PMF and
      ET.

      Although MPNs are diseases of elderly, MPN is diagnosed in younger age groups in a
      considerable number of cases. Since most of the available data as well as current WHO
      classification criteria emphases on the &quot;average&quot; MPN patients who range in age between 55
      and 65 years. Less consistent data are available in the groups of patients presenting below
      this median age, such as children and younger adults which we're planning to reveal.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 11, 2017</start_date>
  <completion_date type="Anticipated">June 1, 2018</completion_date>
  <primary_completion_date type="Anticipated">May 1, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluate the uptake of 3'-deoxy-3'-[18F] fluorothymidine (FLT) positron emission tomography/computed tomography (PET) in children with MPNs</measure>
    <time_frame>12 Months</time_frame>
    <description>Evaluate the uptake of 3'-deoxy-3'-[18F] fluorothymidine (FLT) positron emission tomography/computed tomography (PET) imaging and it is value in assessing the malignant hematopoiesis in children with MPNs.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of patients who have similar diagnosis and pattern between FLT and Bone Marrow</measure>
    <time_frame>12 months</time_frame>
    <description>Assessing of WHO diagnostic criteria for diagnosing MPNs. Measurements would include: Bone marrow cellularity, trilineal assessment, megakaryocytic morphologic characteristics (atypia, clustering, size, lobulation), staging of primary myelofibrosis into prefibrotic/early stage, Primary myelofibrosis and overt fibrotic stage prefibrotic, grade of fibrosis, blast percentage, presence of transformation, intrasinusoidal hematopoiesis, dysplasia (if present).</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Essential Thrombocythemia</condition>
  <condition>Primary Myelofibrosis, Fibrotic Stage</condition>
  <condition>Primary Myelofibrosis, Prefibrotic Stage</condition>
  <condition>Polycythemia Vera</condition>
  <arm_group>
    <arm_group_label>18F-FLT PET/CT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients undergo 18F-FLT (3'-18Fluoro-3'-deoxy-Lthymidine) PET/CT (Positron Emission Tomography/ Computed Tomography) at baseline. No specific dietary restrictions or hydration are required for FLT-PET scans, however, patients will be urged to drink plenty of water before and after the PET studies. [18F] FLT will be prepared by the cyclotron core facility and assessed for quality control following &quot;good manufacturing practice&quot; criteria. The radiopharmaceutical will immediately be brought to the Molecular Imaging and Therapy Service Radiopharmacy for dispensation in the PET suite. For each scan, patients will receive approximately up to 370 MBq (target of 10 mCi) [18F] FLT by intravenous infusion.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Diagnostic (18F-FLT PET/CT)</intervention_name>
    <description>The tracer compound [F-18] FLT will be injected into the patient's veins in a small volume of normal saline solution. The PET scan data collection is started immediately and is continued for 2 hours.</description>
    <arm_group_label>18F-FLT PET/CT</arm_group_label>
    <other_name>18F-FLT PET/CT</other_name>
    <other_name>3'-Deoxy-3'-(18F) Fluorothymidine</other_name>
    <other_name>3'-deoxy-3'-[18F]fluorothymidine</other_name>
    <other_name>Fluorothymidine F 18</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Cases fulfilling WHO (World Health Organization) 2016 diagnostic criteria for MPN
             including: Chronic myeloid leukemia, BCR-ABL1-positive (BCR-ABL = fusion gene from BCR
             (breakpoint cluster region gene/BCR gene product), Chronic neutrophilic leukemia
             (CNL), Polycythemia vera, Primary myelofibrosis prefibrotic/early stage, Primary
             myelofibrosis overt fibrotic stage, Essential thrombocythemia, Chronic eosinophilic
             leukemia, not otherwise specified (NOS) and Myeloproliferative neoplasm,
             unclassifiable.

          -  Age between 14 and 18 years old

          -  Patient accepts to sign inform consent

          -  ECOG (Eastern Cooperative Oncology Group) performance less than or equal 2

        Exclusion Criteria:

          -  Patient not fulfilling the inclusion criteria.

          -  Vulnerable groups: pregnant, minors, prisoners will not be included.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>14 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mohamed Yassin</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hamad Medical Corporation</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mohamed Yassin</last_name>
    <phone>55037393</phone>
    <email>yassin@hamad.qa</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Abdulqadir Nashwan</last_name>
    <phone>66473549</phone>
    <email>anashwan@hamad.qa</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>National Center for Cancer Care &amp; Research (NCCCR)</name>
      <address>
        <city>Doha</city>
        <country>Qatar</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Abdulqadir Nashwan</last_name>
      <phone>66473549</phone>
      <email>anashwan@hamad.qa</email>
    </contact>
    <investigator>
      <last_name>Mohamed A Yassin</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ahmad Al Sabbagh</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Firyal Ibrahim</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dina Soliman</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Samah Kohla</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sadek Nehmeh</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lajos Szabados</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Stefan Guhlke</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Halima El-Omari</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Shehab Mohamed</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Omar Ismail</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Abdulqadir J. Nashwan</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Qatar</country>
  </location_countries>
  <reference>
    <citation>Pikman Y, Lee BH, Mercher T, McDowell E, Ebert BL, Gozo M, Cuker A, Wernig G, Moore S, Galinsky I, DeAngelo DJ, Clark JJ, Lee SJ, Golub TR, Wadleigh M, Gilliland DG, Levine RL. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med. 2006 Jul;3(7):e270.</citation>
    <PMID>16834459</PMID>
  </reference>
  <reference>
    <citation>Beer PA, Campbell PJ, Scott LM, Bench AJ, Erber WN, Bareford D, Wilkins BS, Reilly JT, Hasselbalch HC, Bowman R, Wheatley K, Buck G, Harrison CN, Green AR. MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort. Blood. 2008 Jul 1;112(1):141-9. doi: 10.1182/blood-2008-01-131664. Epub 2008 May 1.</citation>
    <PMID>18451306</PMID>
  </reference>
  <reference>
    <citation>Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, Bloomfield CD, Cazzola M, Vardiman JW. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016 May 19;127(20):2391-405. doi: 10.1182/blood-2016-03-643544. Epub 2016 Apr 11. Review.</citation>
    <PMID>27069254</PMID>
  </reference>
  <reference>
    <citation>Agool A, Schot BW, Jager PL, Vellenga E. 18F-FLT PET in hematologic disorders: a novel technique to analyze the bone marrow compartment. J Nucl Med. 2006 Oct;47(10):1592-8.</citation>
    <PMID>17015893</PMID>
  </reference>
  <reference>
    <citation>Chalkidou A, Landau DB, Odell EW, Cornelius VR, O'Doherty MJ, Marsden PK. Correlation between Ki-67 immunohistochemistry and 18F-fluorothymidine uptake in patients with cancer: A systematic review and meta-analysis. Eur J Cancer. 2012 Dec;48(18):3499-513. doi: 10.1016/j.ejca.2012.05.001. Epub 2012 May 31. Review.</citation>
    <PMID>22658807</PMID>
  </reference>
  <reference>
    <citation>Chen W, Cloughesy T, Kamdar N, Satyamurthy N, Bergsneider M, Liau L, Mischel P, Czernin J, Phelps ME, Silverman DH. Imaging proliferation in brain tumors with 18F-FLT PET: comparison with 18F-FDG. J Nucl Med. 2005 Jun;46(6):945-52.</citation>
    <PMID>15937304</PMID>
  </reference>
  <reference>
    <citation>Ott K, Herrmann K, Schuster T, Langer R, Becker K, Wieder HA, Wester HJ, Siewert JR, zum Büschenfelde CM, Buck AK, Wilhelm D, Ebert MP, Peschel C, Schwaiger M, Lordick F, Krause BJ. Molecular imaging of proliferation and glucose utilization: utility for monitoring response and prognosis after neoadjuvant therapy in locally advanced gastric cancer. Ann Surg Oncol. 2011 Nov;18(12):3316-23. doi: 10.1245/s10434-011-1743-y. Epub 2011 May 3.</citation>
    <PMID>21537865</PMID>
  </reference>
  <reference>
    <citation>Ott K, Rachakonda PS, Panzram B, Keller G, Lordick F, Becker K, Langer R, Buechler M, Hemminki K, Kumar R. DNA repair gene and MTHFR gene polymorphisms as prognostic markers in locally advanced adenocarcinoma of the esophagus or stomach treated with cisplatin and 5-fluorouracil-based neoadjuvant chemotherapy. Ann Surg Oncol. 2011 Sep;18(9):2688-98. doi: 10.1245/s10434-011-1601-y. Epub 2011 Feb 24.</citation>
    <PMID>21347786</PMID>
  </reference>
  <reference>
    <citation>Graf N, Herrmann K, den Hollander J, Fend F, Schuster T, Wester HJ, Senekowitsch-Schmidtke R, zum Büschenfelde CM, Peschel C, Schwaiger M, Dechow T, Buck AK. Imaging proliferation to monitor early response of lymphoma to cytotoxic treatment. Mol Imaging Biol. 2008 Nov-Dec;10(6):349-55. doi: 10.1007/s11307-008-0162-3. Epub 2008 Aug 14.</citation>
    <PMID>18704591</PMID>
  </reference>
  <reference>
    <citation>Leonard JP, LaCasce AS, Smith MR, Noy A, Chirieac LR, Rodig SJ, Yu JQ, Vallabhajosula S, Schoder H, English P, Neuberg DS, Martin P, Millenson MM, Ely SA, Courtney R, Shaik N, Wilner KD, Randolph S, Van den Abbeele AD, Chen-Kiang SY, Yap JT, Shapiro GI. Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma. Blood. 2012 May 17;119(20):4597-607. doi: 10.1182/blood-2011-10-388298. Epub 2012 Mar 1.</citation>
    <PMID>22383795</PMID>
  </reference>
  <reference>
    <citation>Zhang CC, Yan Z, Li W, Kuszpit K, Painter CL, Zhang Q, Lappin PB, Nichols T, Lira ME, Affolter T, Fahey NR, Cullinane C, Spilker M, Zasadny K, O'Brien P, Buckman D, Wong A, Christensen JG. [(18)F]FLT-PET imaging does not always &quot;light up&quot; proliferating tumor cells. Clin Cancer Res. 2012 Mar 1;18(5):1303-12. doi: 10.1158/1078-0432.CCR-11-1433. Epub 2011 Dec 14.</citation>
    <PMID>22170262</PMID>
  </reference>
  <reference>
    <citation>Shields AF, Grierson JR, Dohmen BM, Machulla HJ, Stayanoff JC, Lawhorn-Crews JM, Obradovich JE, Muzik O, Mangner TJ. Imaging proliferation in vivo with [F-18]FLT and positron emission tomography. Nat Med. 1998 Nov;4(11):1334-6.</citation>
    <PMID>9809561</PMID>
  </reference>
  <reference>
    <citation>Vesselle H, Salskov A, Turcotte E, Wiens L, Schmidt R, Jordan CD, Vallières E, Wood DE. Relationship between non-small cell lung cancer FDG uptake at PET, tumor histology, and Ki-67 proliferation index. J Thorac Oncol. 2008 Sep;3(9):971-8. doi: 10.1097/JTO.0b013e31818307a7.</citation>
    <PMID>18758298</PMID>
  </reference>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 17, 2017</study_first_submitted>
  <study_first_submitted_qc>April 17, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 20, 2017</study_first_posted>
  <last_update_submitted>July 24, 2017</last_update_submitted>
  <last_update_submitted_qc>July 24, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 26, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Primary Myelofibrosis</mesh_term>
    <mesh_term>Polycythemia</mesh_term>
    <mesh_term>Polycythemia Vera</mesh_term>
    <mesh_term>Myeloproliferative Disorders</mesh_term>
    <mesh_term>Thrombocytosis</mesh_term>
    <mesh_term>Thrombocythemia, Essential</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alovudine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

